

# Exhibit 1

**REDACTED IN ITS  
ENTIRETY**

# Exhibit 2

## Part 1



Orion Armon  
+1 720 566 4119  
oarmon@cooley.com

May 30, 2019

Andrew J. Danford  
WilmerHale  
60 State Street  
Boston, MA 02109 USA

**Re: Genentech, Inc. et al. v. Amgen, Inc. (18-924-CFC) –Document Production**

Dear Andrew:

We write to follow up on several issues related to Genentech's deficient document productions.

**Genentech's production of financial and other damages-related documents is deficient.**

Genentech's production of financial information is still incomplete. As we noted in our April 24, April 26, and April 27 letters, Genentech has not supplemented its production of financial information and other damages-related documents to adequately cover the time period of November 2018 through the present.

Genentech's production is deficient in the following areas:

- In light of Ms. Oliger's role as the Senior Vice President of BioOncology, we would expect to see numerous materials involving Ms. Oliger related to the Herceptin business, product strategy, forecasting, and biosimilar planning, but the [REDACTED] Please supplement Genentech's production of financial, business planning, and strategy documents to cover the period from fall 2018 through the present.
- Roche's Q1 2019 quarterly reports and financial updates have not been produced.
- Although Genentech has produced [REDACTED], Genentech has not produced current data reflecting (a) gross and net sales units; (b) a description of all adjustments, broken out into the categories maintained in the regular course of business, to gross sales made to yield net sales in dollars and units; and (c) costs of goods sold, broken out into the categories maintained in the regular course of business for these products. See Amgen's Requests for Production No. 28.
- Genentech has not produced documents sufficient to show patient use and/or physician's prescribing of HER2-positive breast cancer treatments, including Herceptin's market share and use by indication across indications. See Amgen's Requests for Production Nos. 23, 57, 66. Genentech has produced [REDACTED]




Andrew J. Danford  
Page Two

**Genentech has not remedied the production of documents stating only “file could not be printed.”**

Pursuant to your letter dated April 28, 2019, Genentech represented they are investigating the availability of documents produced with the slip-sheet “file could not be printed.” We have not received a response as to whether Genentech will be able to produce this information. Please provide an update on this issue.

**Genentech has not produced relevant documents discussed in the Baughman deposition.**



Please confirm that the missing item(s) will be produced immediately. To confirm, Amgen requests that *all* responsive Baughman files be produced, in original native form if necessary, including any pharmacokinetic simulation software outputs that may require special software to access. Amgen further requests written confirmation that all such files have been produced or a date certain by when they will be.

**Genentech’s improper confidentiality designations.**

Genentech’s May 24, 2019 production bearing Bates numbers GNE-HER\_002954560–2954838 has been designated “Highly Confidential–Third Party.” This is not a proper designation under the Protective Order in this case. Amgen assumes this designation was inadvertent and will treat the documents as “Confidential Discovery Material” as provided by the Protective Order.

Sincerely,

A handwritten signature in blue ink, appearing to read "Orion Armon".

Orion Armon

204461834

# Exhibit 2

## Part 2

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.